dasatinib + exemestane

Dasatinib + exemestane is a combination therapy under investigation for the treatment of advanced estrogen receptor-positive (ER+) breast cancer, particularly after progression on non-steroidal aromatase inhibitor (NSAI) therapy. Dasatinib is a small molecule inhibitor targeting multiple tyrosine kinases, including Src family kinases (SFK) and BCR-ABL, and is approved for certain leukemias. Exemestane is an aromatase inhibitor that blocks estrogen biosynthesis, suppressing growth of hormone receptor-positive breast cancer cells. The rationale for combining dasatinib with exemestane is to enhance anti-tumor activity and delay disease progression, especially in cases of endocrine resistance, through dual inhibition of tumor signaling and estrogen synthesis[1][4].

Brand names

AromasinSprycelPhyrago